Actinogen Medical (ASX: ACW) has now enrolled 60 participants in its phase 2b/3 XanaMIA trial of Xanamem, its treatment candidate for Alzheimer's disease, and expects to reach 100 by the end of the quarter, triggering an interim data analysis, according to a Wednesday statement by the company.
The trial targets Alzheimer's disease patients with elevated pTau181 levels, a biomarker linked to disease progression, to better detect Xanamem's treatment benefit.
Final results for the full 220 participants are expected in the fourth quarter of 2026.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。